US regulatory exclusivity periods

United States, federal statutes read together. Regulatory exclusivity is granted by the FDA under several statutes: five years of new chemical entity exclusivity and three years of new clinical investigation exclusivity under Hatch-Waxman (1984); seven years of orphan exclusivity under the Orphan Drug Act (1983); twelve years for a reference biologic under the BPCIA (2010); six months of paediatric exclusivity added to all of the above under BPCA (2002); and 180 days of generic exclusivity for the first successful patent challenger. Primary text: the FDA's patents and exclusivity FAQ lists each with its statutory citation.

How it works: exclusivity runs from approval and does not depend on having a patent, so it matters most for drugs whose patents are weak or expire early, and for biologics where patents are hard to design around. Patents and exclusivity run in parallel; the later date controls when a generic or biosimilar can launch, which is the logic behind the exclusivity timeline on this site. Orphan exclusivity blocks only the same drug for the same indication, and a company can stack orphan indications to extend protection.

The arguments: the twelve-year biologic term is the longest in the world and the Obama and Trump administrations both proposed cutting it; small-molecule sponsors argue the five-year term is short and that the Inflation Reduction Act's earlier negotiation clock for pills compounds the gap. The European Union's 8+2+1 system and Japan's re-examination period are the comparators.